论文部分内容阅读
最近,人力资源和社会保障部对外公布了36种药品进入医保目录后的价格谈判结果,并且同步确定了这些药品的医保支付标准。这一谈判,是由人社部主导的“2017年国家医保药品目录准入谈判工作”的成果,目的就是为了减轻参保人员药品费用负担、提高医保基金的使用效率等。通过公布的药品名单可以看出,此次被纳入医保范围的药品,大多都是肿瘤靶向药,以及治疗心血管病、血友病等重大疾病的药品,其价值和需求都非常
Recently, the Ministry of Human Resources and Social Security announced the outcome of price negotiations on the 36 drugs entering the medical insurance catalog, and simultaneously determined the standard of medical insurance for these drugs. This negotiation is the result of the “approval of the 2017 national medical insurance drug list access negotiation” led by the Ministry of Human Resources and Social Security to reduce the burden on drug users and increase the efficiency of using the medical insurance fund. The list of released drugs shows that most of the drugs included in the scope of medical insurance are tumor-targeted drugs and drugs for treating major diseases such as cardiovascular diseases and hemophilia, and their value and demand are very high